同: DPT vaccine

WordNet

an acute and serious infection of the central nervous system caused by bacterial infection of open wounds; spasms of the jaw and laryngeal muscles may occur during the late stages (同)lockjaw
a sustained muscular contraction resulting from a rapid series of nerve impulses
immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum
acute contagious infection caused by the bacterium Corynebacterium diphtheriae; marked by the formation of a false membrane in the throat and other air passages causing difficulty in breathing

PrepTutorEJDIC

破傷風
牛痘種,痘苗(牛痘を起こすビールスで,天然痘予防のために人体に接種される) / (伝染病の病原菌から作った)ワクチン
ジフテリア(呼吸困難を起こすのどの病気)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/12/17 01:57:14」(JST)

wiki en

DPT (also DTP and DTwP) refers to a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus. The vaccine components include diphtheria and tetanus toxoids and killed whole cells of the bacterium that causes pertussis (wP).

DTaP and Tdap refer to similar combination vaccines in which the component with lower case "a" is acellular.

Also available are the DT and Td vaccines, which lack the pertussis component.

In the United Kingdom, the Netherlands and France, the abbreviation DTP refers to a combination vaccine against diphtheria, tetanus, and poliomyelitis. In the Netherlands, pertussis is known as kinkhoest and DKTP refers to a combination vaccine against diphtheria, kinkhoest, tetanus, and polio.

The usual course of childhood immunization in the USA is five doses between 2 months and 15 years. For adults, Td boosters are recommended every 10 years..

In the latter 20th century, vaccinations helped to reduce the incidence of childhood pertussis in the United States. Despite this, reported instances of the disease increased twenty-fold in the early 21st century, resulting in numerous fatalities.^[1] Over this time, many parents declined to vaccinate their children against pertussis for fear of side effects.^[1] In 2009, The journal Pediatrics concluded the largest risk among unvaccinated children was not the contraction of side effects, but rather the disease that the vaccination aims to protect against.^[1]

DTP was licensed in 1949.^[2]

Combination vaccines with acellular pertussis

DTaP and Tdap are both combined vaccines against diphtheria, tetanus, and pertussis. The difference is in the dosage, with the upper case letters meaning higher quantity.^[3] The names are easy to confuse, and the Institute for Safe Medication Practices reports hundreds of cases of accidental mix-ups.^[4]

DTaP

DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the component with lower case 'a' is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP's narrower antigen base is less effective against current pathogen strains.^[5]

Recent research in non human primates has shown that while DTaP does confer immunity, it does not prevent transmission because it does not prevent Pertussis from colonizing the airways of vaccinated individuals. Thus non human primates who have received DTaP can infect unvaccinated or immunocompromised non human primates.^[6] Other recent research has shown that DTaP confers less immunity than whole cell DTP (aka DTwP).^[7]

Tdap

On June 10, 2005, a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) was licensed in the United States for use in adults and adolescents. ^[8] The lower case "d" and "p" indicated smaller concentrations of diphtheria toxoids and pertussis antigens, and "a" in "ap" indicates that the pertussis toxoids are acellular. Two Tdap vaccines are available in the U.S. Adacel, manufactured by Sanofi Pasteur, is licensed for use in adults ages 11 to 64. Boostrix, manufactured by GlaxoSmithKline, is licensed for use in adolescents and adults ages 10 to 64. After the 2010 passage of Assembly Bill 354, the State of California requires all students entering grades 7-12 provide proof of Tdap vaccination as a condition of enrollment in both public and private schools.^[9] In January 2011, the U.S.'s Advisory Committee on Immunization Practices (ACIP) recommended Tdap's use in adults of all ages, including those age 65 and above. ^[10] In October 2011, in an effort to reduce the burden of pertussis in infants, the ACIP recommended that unvaccinated pregnant women receive a dose of Tdap. On October 24, 2012, the ACIP voted to recommend use of Tdap during every pregnancy. ^[11]

The U.S.'s Advisory Committee on Immunization Practices (ACIP) and Canada's National Advisory Committee on Immunization (NACI) recommended that both adolescents and adults receive Tdap in place of their next Td booster (recommended to be given every 10 years).^[12]^[13]^[14]^[15] Tdap and Td can be used as prophylaxis for tetanus in wound management. People who will be in contact with young infants are encouraged to get Tdap even if it has been less than 5 years since Td or TT to reduce the risk of infants being exposed to pertussis. The ACIP statement on Tdap use in adolescents encourages 5 years between Td and Tdap to reduce the risk of side effects;^{[citation needed]} however, both suggest that shorter intervals may be appropriate in some circumstances, such as for protection in pertussis outbreaks. NACI suggests intervals shorter than 5 years can be used for catch-up programs and other instances where programmatic concerns make 5-year intervals difficult.^{[citation needed]}

Thiomersal

Thiomersal (INN), commonly known in the US as thimerosal, is an organomercury compound used as a preservative in certain vaccines. Out of the eight manufactured DPT vaccines^[where?], only three ever contained thiomersal. Currently, seven out of the eight DPT vaccines on the market do not use thiomersal, and the product that does (Tripedia) contains trace levels, less than 0.3 micrograms per dose.^[16] The World Health Organization has concluded that there is no evidence of toxicity from thiomersal in vaccines.^[17] However, following a review of mercury-containing food and drugs mandated in 1999, the Centers for Disease Control (CDC) and the American Academy of Pediatrics asked vaccine manufacturers to remove thiomersal from vaccines as a purely precautionary measure, and it was rapidly phased out of most U.S. and European vaccines.^[18]^[19]

Medication errors

In August 2006, the non-profit patient safety organization Institute for Safe Medication Practices described medication errors from the confusion between the two different formulations.^[20]

There were several mix-ups between DAPTACEL and ADACEL. Daptacel is for active immunization in infants and children 6 weeks to 6 years old. Adacel is indicated for active booster immunization as a single dose in persons 11 to 64 years old and is the first vaccine approved as a pertussis booster for adults. The component antigens in Adacel and Daptacel are the same, but the relative amounts are much greater with the infant vaccination.^{[citation needed]}

In one clinic, 13 adults were vaccinated with Daptacel in error. At another clinic, seven adults received Daptacel instead of Adacel. None of the patients appeared to have experienced any unusual vaccine reactions despite the fact that the pediatric formulation contains greater amounts of the detoxified pertussis toxin and diphtheria toxoid. The similarities of the brand names, generic designations, and vaccine abbreviations (Tdap and DTaP) were felt to have contributed to the confusion.^{[citation needed]}

The World Health Organization recommends a pentavalent vaccine, combining the DTP vaccine with vaccines against Haemophilus influenzae type B and hepatitis B. There is not yet sufficient evidence on how effective this pentavalent vaccine is compared to the individual vaccines.^[21]

In pregnancy

Guidelines on prenatal care in the United States state that, if an urgent need for tetanus protection occurs during pregnancy, Td vaccine should be administered.^[22] If no urgent need arises and the woman has previously received tetanus vaccine, Td vaccination should be delayed until the postpartum period.^[22] All postpartum women who have not received Td or Tdap vaccine in the last two years are recommended to receive Tdap prior to discharge after delivery.^[22] It is recommended for pregnant women who have never received tetanus vaccine (i.e., have never received DTP, DTaP or DT as child or Td or TT as adult) to receive a series of three Td vaccinations starting during pregnancy to ensure protection against maternal and neonatal tetanus.^[22] In such cases, administration of Tdap is recommended after 20 weeks' gestation,^[23] and in earlier pregnancy a single dose of Tdap can be substituted for one dose of Td, and then the series completed with Td.^[22] The United States Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend that health-care personnel should administer a dose of Tdap during each pregnancy at 27 through 36 weeks gestation irrespective of the patient's prior history of receiving Tdap.^[24]

Purported non-specific effects

A systematic review was recently completed on this topic so as to compile and rate all of the available evidence.^[25] This review showed that receipt of DTP had no significant non-specific effect on all-cause mortality (relative risk 1.38, 0.92 to 2.08). In addition, it showed that many of the studies reporting on this topic were at a high risk of bias.^[25] The WHO has recommended that further studies, which are well designed and reflect current vaccine schedules, be carried out on this topic.^[26]

DTP vaccine seem to have negative non-specific effects on survival rate of children in high-mortality countries in Africa and Asia^[27] The negative effects are seen as long as DTP vaccine is the most recent vaccine. BCG or measles vaccine given after DTP reverses the negative effects of DTP.^[27] The negative effects are seen mostly in females.^[27]

The negative effects are found in several observational studies. However, six WHO-commissioned studies concluded that there were strong beneficial effects of DTP on overall mortality.^[28]^[29]^[30]^[31]^[32]^[33] However, controversy ensued as to the design of these studies that had important methodological shortcomings.^[34]^[35] Among others, the WHO-commissioned studies had counted “no information about vaccination” as “unvaccinated”, and they had retrospectively updated vaccine information from surviving children, while no similar update could be made for dead children, creating a so-called “survival bias” which will always produce highly beneficial effect estimates for the most recent vaccine.^[36]

References

^ ^a ^b ^c "Is Vaccine Refusal Worth The Risk?". NPR. National Public Radio. 2009-05-26. Retrieved 2009-06-19.
^ "Vaccine Timeline: Historic Dates and Events Related to Vaccines and Immunization". Immunization Action Coalition. 2013-05-17. Retrieved 2014-06-25.
^ "The difference between Tdap and DTaP; dabigatran versus warfarin". JAAPA. Retrieved 2014-06-25.
^ "DTaP-Tdap mix-ups now affecting hundreds of patients". Ismp.org. Retrieved 2014-06-25.
^ Higgs, Higgins, Ross and Mills 2012 'Immunity to the respiratory pathogen Bordatella pertussis' Mucosal Immunol 5(5):485-500
^ Warfel JM, Zimmerman LI, Merkel TJ (2013). "Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model". Proceedings of the National Academy of Sciences. 111 (2): 787–792. doi:10.1073/pnas.1314688110. ISSN 0027-8424. PMC 3896208 . PMID 24277828.
^ "Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers". Pediatrics.AAPPublications.org. Retrieved 2014-06-25.
^ "Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel". MMWR Morb. Mortal. Wkly. Rep. 55: 1–33. December 15, 2016.
^ California State Legislature (September 29, 2010). "AB 354 Assembly Bill". Legislative Counsel of California. Retrieved 2012-06-09.
^ "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010". MMWR Morb. Mortal. Wkly. Rep. 60 (1): 13–5. January 2011. PMID 21228763.
^ "Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012". MMWR Morb. Mortal. Wkly. Rep. 62 (7): 131–135. February 22, 2013.
^ Broder KR, Cortese MM, Iskander JK, et al. (Mar 2006). "Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 55 (RR–3): 1–34. PMID 16557217. , page 18.
^ "ACIP Votes to Recommend Use of Combined Tetanus, Diphtheria and Pertussis (Tdap) Vaccine for Adults" (PDF). CDC.gov. Centers for Disease Control and Prevention. Archived from the original (PDF) on 2006-10-19.
^ "Interval Between Administration of Vaccines Against Diphtheria, Tetanus, and Pertussis". PHAC-ASPC.GC.ca.
^ Kretsinger K, Broder KR, Cortese MM, et al. (December 2006). "Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel". MMWR Recomm Rep. 55 (RR–17): 1–37. PMID 17167397.
^ United States Food and Drug Administration. "Thiomersal in Vaccines".
^ Global Advisory Committee on Vaccine Safety (2006-07-14). "Thiomersal and vaccines". World Health Organization. Retrieved 2007-11-20.
^ Baker JP (2008). "Mercury, Vaccines, and Autism: One Controversy, Three Histories". Am J Public Health. 98 (2): 244–53. doi:10.2105/AJPH.2007.113159. PMC 2376879 . PMID 18172138.
^ "Thimerosal in vaccines: frequently asked questions (FAQs)". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. 2007-06-07. Retrieved 2008-07-22.
^ "Adacel (Tdap) and Daptacel (DTaP) confusion". ISMP Medication Safety Alert!. Institute for Safe Medication Practices. August 24, 2006.
^ Bar-On ES, Goldberg E, Hellmann S, Leibovici L (2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". Cochrane Database Syst Rev. 4 (4): CD005530. doi:10.1002/14651858.CD005530.pub3. PMID 22513932.
^ ^a ^b ^c ^d ^e Health Care Guideline: Routine Prenatal Care. Fourteenth Edition. Archived June 24, 2012, at the Wayback Machine. By the Institute for Clinical Systems Improvement. July 2010.
^ Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged <12 Months, 2011 - section "Safety of Tdap in Pregnant Women". By the Advisory Committee on Immunization Practices (ACIP), at Centers for Disease Control and Prevention.
^ [1] Archived January 23, 2013, at the Wayback Machine.
^ ^a ^b Higgins, Julian P. T.; Soares-Weiser, Karla; López-López, José A.; Kakourou, Artemisia; Chaplin, Katherine; Christensen, Hannah; Martin, Natasha K.; Sterne, Jonathan A. C.; Reingold, Arthur L. (13 October 2016). "Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review". BMJ. 355: i5170. doi:10.1136/bmj.i5170. PMID 27737834. Retrieved 29 November 2017 – via www.bmj.com.
^ "WHO - SAGE meeting of April 2014". www.who.int. Retrieved 29 November 2017.
^ ^a ^b ^c Aaby, P; Benn, C; Nielsen, J; Lisse, IM; Rodrigues, A; Ravn, H (22 May 2012). "Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries". BMJ Open. 2 (3): e000707. doi:10.1136/bmjopen-2011-000707. PMC 3364456 . PMID 22619263.
^ Nyarko, P; Pence, B; Debpuur, C (2001). "Immunization status and child survival in rural Ghana". Population council. Working papers no. 147.
^ Lehmann, D; Vail, J; Firth, MJ; de Klerk, NH; Alpers, MP (Feb 2005). "Benefits of routine immunizations on childhood survival in Tari, Southern Highlands Province, Papua New Guinea". Int J Epidemiol. 34 (1): 138–48. doi:10.1093/ije/dyh262. PMID 15561755.
^ Elguero, E; Simondon, KB; Vaugelade, J; Marra, A; Simondon, F (October 2010). "Non-specific effects of vaccination on child survival? A prospective study in Senegal". Trop Med Int Health. 10 (10): 956–60. doi:10.1111/j.1365-3156.2005.01479.x. PMID 16185229.
^ Vaugelade, J; Pinchinat, S; Guiella, G; Elguero, E; Simondon, F (4 December 2004). "Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso". BMJ. 329 (7478): 1309. doi:10.1136/bmj.38261.496366.82. PMC 534835 . PMID 15550402.
^ Moulton, LH; Rahmathullah, L; Halsey, NA; Thulasiraj, RD; Katz, J; Tielsch, JM (October 2005). "Evaluation of non-specific effects of infant immunizations on early infant mortality in a southern Indian population". Trop Med Int Health. 10 (10): 947–55. doi:10.1111/j.1365-3156.2005.01434.x. PMID 16185228.
^ Breiman, RF; Streatfield, PK; Phelan, M; Shifa, N; Rashid, M; Yunus, M (December 2004). "Effect of infant immunisation on childhood mortality in rural Bangladesh: analysis of health and demographic surveillance data". Lancet. 364 (9452): 2204–11. doi:10.1016/s0140-6736(04)17593-4. PMID 15610807.
^ Aaby, P; Benn, CS; Nielsen, J; Lisse, IM; Rodrigues, A; Jensen, H (Jan 2007). "DTP vaccination and child survival in observational studies with incomplete vaccination data". Trop Med Int Health. 12 (1): 15–24. doi:10.1111/j.1365-3156.2006.01774.x. PMID 17207144.
^ Fine, PEM; Smith, PG (2007). "Editorial: 'Non-specific effects of vaccines'- an important analytical insight, and call for a workshop". Trop Med Int Health. 12 (1): 1–4. doi:10.1111/j.1365-3156.2006.01794.x. PMID 17207142.
^ Jensen, H; Benn, CS; Lisse, IM; Rodrigues, A; Andersen, PK; Aaby, P (Jan 2007). "Survival bias in observational studies of the impact of routine immunizations on childhood survival". Trop Med Int Health. 12 (1): 5–14. doi:10.1111/j.1365-3156.2006.01773.x. PMID 17207143.

External links

Tdap Vaccine: What You Need to Know, vaccine information statement (5/9/2013 release)
Td or Tdap Vaccine: What You Need to Know, vaccine information statement (5/17/2007 release)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 0～6歳の乳児および小児におけるジフテリア、破傷風、および百日咳ワクチン diphtheria tetanus and pertussis immunization in infants and children 0 through 6 years of age
2. 7～18歳の小児におけるジフテリア、破傷風、および百日咳ワクチン diphtheria tetanus and pertussis immunization in children 7 through 18 years of age
3. 思春期および成人における百日咳菌感染症の治療および予防 treatment and prevention of bordetella pertussis infection in adolescents and adults
4. 成人における破傷風-ジフテリアトキソイドワクチン tetanus diphtheria toxoid vaccination in adults
5. 予防接種に対する免疫応答の評価 assessing the immunologic response to vaccination

English Journal

Hexavalent vaccines for immunization in paediatric age.

Esposito S1, Tagliabue C, Bosis S, Ierardi V, Gambino M, Principi N.Author information 1Paediatric High Intensity Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.AbstractDespite the potential for protection against a broad spectrum of pathogens, the availability of an increased number of effective vaccines could lead to a significant reduction in vaccination coverage as the result of issues with implementation of new vaccines within existing protocols. To overcome these problems, the development of combined vaccines has been promoted. The use of combined vaccines offers a number of potential benefits, including a reduction in the number of patient visits, reduced complications associated with multiple intramuscular injections, decreased costs of stocking and administering separate vaccines, and a lowering of the risk of delayed or missed vaccinations. The hexavalent vaccine includes antigens against diphtheria, tetanus, acellular pertussis (DTaP), hepatitis B (HBsAg), poliomyelitis (P1, P2, P3) and Haemophilus influenzae type B (Hib) infections. The primary goal of this review is to discuss the immunogenicity, efficacy, safety and tolerability of several hexavalent preparations that are either commercially available or still under development.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.Clin Microbiol Infect.2014 May;20 Suppl 5:76-85. doi: 10.1111/1469-0691.12444. Epub 2014 Jan 24.
Despite the potential for protection against a broad spectrum of pathogens, the availability of an increased number of effective vaccines could lead to a significant reduction in vaccination coverage as the result of issues with implementation of new vaccines within existing protocols. To overcome t
PMID 24460910

Antibody and Cell-mediated Immunity to Pertussis 4 Years After Monovalent Acellular Pertussis Vaccine at Birth.

Wood N1, Marshall H, White OJ, Holt PG, McIntyre P.Author information 1From the *National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, New South Wales; †The Children's Hospital, Westmead, Sydney; ‡The University of Sydney, New South Wales, Australia; §Discipline of Paediatrics, School of Paediatrics and Reproductive Health and the Robinson Institute, The University of Adelaide; ¶Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Women's and Children's Health Network, South Australia; ‖Telethon Institute for Child Health Research and Centre for Child Health Research, Faculty of Medicine and Dentistry, The University of Western Australia, Perth; and **Queensland Children's Medical Research Institute, University of Queensland, Brisbane, Queensland, Australia.AbstractBACKGROUND: In a previous study, we found that monovalent acellular pertussis (aP) vaccine at birth and 1 month achieves higher IgG antibody (Ab) levels to pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin by 8 weeks, when compared with controls. Here, we report antibody and cell-mediated immune responses to 4 years of age.
The Pediatric infectious disease journal.Pediatr Infect Dis J.2014 May;33(5):511-7. doi: 10.1097/INF.0000000000000246.
BACKGROUND: In a previous study, we found that monovalent acellular pertussis (aP) vaccine at birth and 1 month achieves higher IgG antibody (Ab) levels to pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin by 8 weeks, when compared with controls. Here, we report antibody and cell-
PMID 24445839

Predictors of optional immunization uptake in an urban south Indian population.

Manthiram K1, Blood EA2, Kuppuswamy V3, Martins Y4, Narayan A5, Burmeister K4, Parvathy K6, Hassan A7.Author information 1Department of Pediatric Infectious Disease, Vanderbilt University School of Medicine, Nashville, TN, United States. Electronic address: Kalpana.manthiram@vanderbilt.edu.2Division of Adolescent Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States; Clinical Research Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.3Medical University of South Carolina, Charleston, SC, United States.4Center for Population Sciences, Dana-Farber Cancer Institute, Boston, MA, United States.5Department of Neonatalogy, Emory Johns Creek Hospital, Johns Creek, GA, United States.6Pallavaram Children's Medical Centre, Pallavaram, Tamil Nadu, India.7Division of Adolescent Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.AbstractBACKGROUND: In Tamil Nadu, India, bacille Calmette-Guérin, diphtheria-tetanus-pertussis, oral poliomyelitis, hepatitis B, and measles vaccines are part of the routine immunization schedule and are available free from government health centers. All other vaccines are optional and available in the private sector at a cost to families. This study assesses immunization rates of routine and optional vaccines and examines parental attitudes toward vaccines in Pallavapuram, Tamil Nadu.
Vaccine.Vaccine.2014 Apr 12. pii: S0264-410X(14)00514-3. doi: 10.1016/j.vaccine.2014.04.012. [Epub ahead of print]
BACKGROUND: In Tamil Nadu, India, bacille Calmette-Guérin, diphtheria-tetanus-pertussis, oral poliomyelitis, hepatitis B, and measles vaccines are part of the routine immunization schedule and are available free from government health centers. All other vaccines are optional and available in the pr
PMID 24736005

Japanese Journal

極低出生体重児でNICU退院後に百日咳のためにPICU管理を要した1例

日本周産期・新生児医学会雑誌 = Journal of Japan Society of Perinatal and Neonatal Medicine 49(1), 52-53, 2013-05-20
NAID 10031176834

Papulopustular eruption following diphtheria-tetanus-pertussis vaccine

Journal of dermatology 38(6), 606-607, 2011-06-01
NAID 10031147052

ジフテリア・破傷風・百日咳(DTP)ワクチン (特集ワクチン up to date)

小児科診療 72(12), 2292-2296, 2009-12
NAID 40016893872

Related Pictures

★リンクテーブル★

「tetanus」

DPT vaccine
Combination of
Diphtheria vaccine	Vaccine
Pertussis vaccine	Vaccine
Tetanus vaccine	Vaccine
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
ChemSpider	none;
(what is this?) (verify)

　　[★]

n.

破傷風
テタヌス、強縮

[vaccine_refusal-1] "Is Vaccine Refusal Worth The Risk?". NPR. National Public Radio. 2009-05-26. Retrieved 2009-06-19.

[2] "Vaccine Timeline: Historic Dates and Events Related to Vaccines and Immunization". Immunization Action Coalition. 2013-05-17. Retrieved 2014-06-25.

[3] "The difference between Tdap and DTaP; dabigatran versus warfarin". JAAPA. Retrieved 2014-06-25.

[4] "DTaP-Tdap mix-ups now affecting hundreds of patients". Ismp.org. Retrieved 2014-06-25.

[5] Higgs, Higgins, Ross and Mills 2012 'Immunity to the respiratory pathogen Bordatella pertussis' Mucosal Immunol 5(5):485-500

[WarfelZimmerman2013-6] Warfel JM, Zimmerman LI, Merkel TJ (2013). "Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model". Proceedings of the National Academy of Sciences. 111 (2): 787–792. doi:10.1073/pnas.1314688110. ISSN 0027-8424. PMC 3896208 . PMID 24277828.

[7] "Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers". Pediatrics.AAPPublications.org. Retrieved 2014-06-25.

[8] "Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel". MMWR Morb. Mortal. Wkly. Rep. 55: 1–33. December 15, 2016.

[9] California State Legislature (September 29, 2010). "AB 354 Assembly Bill". Legislative Counsel of California. Retrieved 2012-06-09.

[10] "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010". MMWR Morb. Mortal. Wkly. Rep. 60 (1): 13–5. January 2011. PMID 21228763.

[11] "Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012". MMWR Morb. Mortal. Wkly. Rep. 62 (7): 131–135. February 22, 2013.

[12] Broder KR, Cortese MM, Iskander JK, et al. (Mar 2006). "Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 55 (RR–3): 1–34. PMID 16557217. , page 18.

[13] "ACIP Votes to Recommend Use of Combined Tetanus, Diphtheria and Pertussis (Tdap) Vaccine for Adults" (PDF). CDC.gov. Centers for Disease Control and Prevention. Archived from the original (PDF) on 2006-10-19.

[14] "Interval Between Administration of Vaccines Against Diphtheria, Tetanus, and Pertussis". PHAC-ASPC.GC.ca.

[15] Kretsinger K, Broder KR, Cortese MM, et al. (December 2006). "Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel". MMWR Recomm Rep. 55 (RR–17): 1–37. PMID 17167397.

[16] United States Food and Drug Administration. "Thiomersal in Vaccines".

[17] Global Advisory Committee on Vaccine Safety (2006-07-14). "Thiomersal and vaccines". World Health Organization. Retrieved 2007-11-20.

[Baker-18] Baker JP (2008). "Mercury, Vaccines, and Autism: One Controversy, Three Histories". Am J Public Health. 98 (2): 244–53. doi:10.2105/AJPH.2007.113159. PMC 2376879 . PMID 18172138.

[19] "Thimerosal in vaccines: frequently asked questions (FAQs)". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. 2007-06-07. Retrieved 2008-07-22.

[20] "Adacel (Tdap) and Daptacel (DTaP) confusion". ISMP Medication Safety Alert!. Institute for Safe Medication Practices. August 24, 2006.

[21] Bar-On ES, Goldberg E, Hellmann S, Leibovici L (2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". Cochrane Database Syst Rev. 4 (4): CD005530. doi:10.1002/14651858.CD005530.pub3. PMID 22513932.

[icsi2010-22] Health Care Guideline: Routine Prenatal Care. Fourteenth Edition. Archived June 24, 2012, at the Wayback Machine. By the Institute for Clinical Systems Improvement. July 2010.

[23] Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged <12 Months, 2011 - section "Safety of Tdap in Pregnant Women". By the Advisory Committee on Immunization Practices (ACIP), at Centers for Disease Control and Prevention.

[24] [1] Archived January 23, 2013, at the Wayback Machine.

[bmj.com-25] Higgins, Julian P. T.; Soares-Weiser, Karla; López-López, José A.; Kakourou, Artemisia; Chaplin, Katherine; Christensen, Hannah; Martin, Natasha K.; Sterne, Jonathan A. C.; Reingold, Arthur L. (13 October 2016). "Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review". BMJ. 355: i5170. doi:10.1136/bmj.i5170. PMID 27737834. Retrieved 29 November 2017 – via www.bmj.com.

[26] "WHO - SAGE meeting of April 2014". www.who.int. Retrieved 29 November 2017.

[(15)-27] Aaby, P; Benn, C; Nielsen, J; Lisse, IM; Rodrigues, A; Ravn, H (22 May 2012). "Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries". BMJ Open. 2 (3): e000707. doi:10.1136/bmjopen-2011-000707. PMC 3364456 . PMID 22619263.

[(21)-28] Nyarko, P; Pence, B; Debpuur, C (2001). "Immunization status and child survival in rural Ghana". Population council. Working papers no. 147.

[(20)-29] Lehmann, D; Vail, J; Firth, MJ; de Klerk, NH; Alpers, MP (Feb 2005). "Benefits of routine immunizations on childhood survival in Tari, Southern Highlands Province, Papua New Guinea". Int J Epidemiol. 34 (1): 138–48. doi:10.1093/ije/dyh262. PMID 15561755.

[(19)-30] Elguero, E; Simondon, KB; Vaugelade, J; Marra, A; Simondon, F (October 2010). "Non-specific effects of vaccination on child survival? A prospective study in Senegal". Trop Med Int Health. 10 (10): 956–60. doi:10.1111/j.1365-3156.2005.01479.x. PMID 16185229.

[(18)-31] Vaugelade, J; Pinchinat, S; Guiella, G; Elguero, E; Simondon, F (4 December 2004). "Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso". BMJ. 329 (7478): 1309. doi:10.1136/bmj.38261.496366.82. PMC 534835 . PMID 15550402.

[(17)-32] Moulton, LH; Rahmathullah, L; Halsey, NA; Thulasiraj, RD; Katz, J; Tielsch, JM (October 2005). "Evaluation of non-specific effects of infant immunizations on early infant mortality in a southern Indian population". Trop Med Int Health. 10 (10): 947–55. doi:10.1111/j.1365-3156.2005.01434.x. PMID 16185228.

[(16)-33] Breiman, RF; Streatfield, PK; Phelan, M; Shifa, N; Rashid, M; Yunus, M (December 2004). "Effect of infant immunisation on childhood mortality in rural Bangladesh: analysis of health and demographic surveillance data". Lancet. 364 (9452): 2204–11. doi:10.1016/s0140-6736(04)17593-4. PMID 15610807.

[(23)-34] Aaby, P; Benn, CS; Nielsen, J; Lisse, IM; Rodrigues, A; Jensen, H (Jan 2007). "DTP vaccination and child survival in observational studies with incomplete vaccination data". Trop Med Int Health. 12 (1): 15–24. doi:10.1111/j.1365-3156.2006.01774.x. PMID 17207144.

[(22)-35] Fine, PEM; Smith, PG (2007). "Editorial: 'Non-specific effects of vaccines'- an important analytical insight, and call for a workshop". Trop Med Int Health. 12 (1): 1–4. doi:10.1111/j.1365-3156.2006.01794.x. PMID 17207142.

[(24)-36] Jensen, H; Benn, CS; Lisse, IM; Rodrigues, A; Andersen, PK; Aaby, P (Jan 2007). "Survival bias in observational studies of the impact of routine immunizations on childhood survival". Trop Med Int Health. 12 (1): 5–14. doi:10.1111/j.1365-3156.2006.01773.x. PMID 17207143.

匿名

検索

案内

案内

diphtheria-tetanus-pertussis vaccine